

Upgraded Product launch and Contract Wins
RNS Number : 8285W
EKF Diagnostics Holdings PLC
18 July 2024

EKF Diagnostics Holdings plc
("EKF", the "Company", or the "Group")

Upgraded Product launch and Contract Wins

*Global launch of new Biosen analyzer
Two contracts in Asia with The Red Cross*

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces the launch of its new and enhanced **Biosen C-Line**, an industry leading benchtop glucose and lactate analyzer within its Point of Care ("POC") range, in response to customer demands for greater connectivity options and improved usability. EKF also announces it has secured new contract wins from two tenders: Hong Kong Red Cross (three years) and Thai Red Cross (two years) worth approximately £600k in total.

The Biosen C-Line (the "Biosen") is an easy-to-use, POC analyzer which accurately measures glucose and lactate levels in healthcare and sports performance. The Biosen is used by clinical professionals in both primary and secondary care settings around the world to provide fast and accurate glucose analysis for the detection and management of diabetes, a chronic condition which is expected to affect 1.31 billion people worldwide by 2050^[1]. The Biosen is also the first choice for elite sports professionals, including international football and Olympic teams, to measure lactate production during training, which provides valuable insights into athletes' metabolic responses during training and competition to help achieve peak performance.

The updated Biosen range uses the same proven technology as its predecessor to provide precise and rapid measurements of glucose and lactate levels in whole blood, plasma and serum with just one test. The new version has been enhanced with improved connectivity, and is fully compatible with [EKF Link](#), a middleware solution for healthcare providers to manage their POC analyzers on one centralised platform to enable the real-time remote management of data. EKF Link is a fast and secure method for

connecting POC devices to hospital and laboratory IT systems, enabling the safe transfer of data from the analyzer to the hospital or laboratory database for subsequent processing.

Integration of technology systems and advanced connectivity is becoming increasingly important to healthcare providers and laboratories around the world, as they look to improve resource utilisation and efficiencies. The addition of EKF Link to the Company's POC portfolio has opened up a number of new tender opportunities around the world, including the Hong Kong and Thai Red Cross partnerships and will continue to aid the Company's growth in the blood bank market globally.

New Biosen C-Line



A user-friendly, enhanced version of the EKF Biosen C-Line (above) has a new look and feel with a colour touchscreen and multi-language capabilities, as well as added connectivity with EKF Link

Julian Baines, Executive Chair of EKF Diagnostics plc, said: *"The launch of the new and enhanced Biosen is in line with our strategy to focus our R&D on developing existing, high-growth, high-margin products and we continue to lead and innovate in this space. We are also encouraged by the growing demand for EKF Link, which is compatible with the EKF POC portfolio as well as other devices, and has improved our competitive positioning, opening a number of new tender opportunities around the world."*

Learn more about the EKF Biosen C-Line analyzer measuring glucose and lactate levels in whole blood, plasma and serum (<https://www.ekfdiagnostics.com/biosen>) and also explore other EKF products: <https://www.ekfdiagnostics.com/>.

For more information visit:

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair
Stephen Young, CFO

via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker) Tel: +44 (0)20 7496 3000
Phil Davies / Oliver Platts

Walbrook PR Limited
Paul McManus / Charlotte Edgar

Tel: +44 (0)20 7933 8780 or
ekf@walbrookpr.com

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Details of the Contract Wins

EKF won two tenders in a competitive process: a three-year contract with the Hong Kong Red Cross and a two-year contract with the Thai Red Cross.

The new contract with the Hong Kong Red Cross is to provide the following:

- 65 Hemo Control Hemoglobin Analyzers
- 870K tests
- Installation of EKF Link to integrate and connect devices to HKRC data management

The Thai Red Cross contract is to provide:

- 233 DiaSpect™ hand-held haemoglobin analysers
- 2.5M DiaSpect tests cuvette

[1] [The Lancet and The Lancet Diabetes & Endocrinology journals \(June 2023\)](#)

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUBANRSOUBAAR